Wolfe, Sidney M.
June 2006
Health Matrix: Journal of Law-Medicine;Summer2006, Vol. 16 Issue 2, p785
Academic Journal
The article discusses issues and topics contained in the book "Worst Pills, Best Pills," by Sidney M. Wolfe. Originally, the book listed about a hundred or so drugs that showed negative side-effects and a corresponding safer alternatives for everyone of them. The purpose of the book, in parallel with the efforts to get the Food and Drug Administration to ban or put stronger warnings on these drugs, is to try to encourage patients to do something about it.


Related Articles

  • Double-Standard Drugs. Clinton, Patrick // Pharmaceutical Executive;Dec2005, Vol. 25 Issue 12, p16 

    This article focuses on the drug approval standards in the U.S. Currently, the public attention is focused on drug safety, but the reality is that most industry critics are focusing on a far narrower issue: drugs that are approved because of having a favorable risk/benefit ratio in a particular...

  • Protect yourself from drug dangers.  // Consumer Reports on Health;Mar2005, Vol. 17 Issue 3, p8 

    Provides information on high risks drugs that are available in the market and approved by the U.S. Food and Drug Administration. List of drugs and their corresponding adverse effects; Failure of the Agency to monitor the safety of the drugs prior to their release in the market; Guidelines that...

  • ISMP Adverse Drug Reactions. . Shuster, Joel // Hospital Pharmacy;Mar2010, Vol. 45 Issue 3, p196 

    The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MEDWATCH program (800-FDA-1088). If you have reported an interesting, preventable ADR to...

  • Study: Adverse drug events on rise.  // AHA News;9/17/2007, Vol. 43 Issue 19, p6 

    The article highlights a study which found an increase in the number of serious adverse drug events reported to the U.S. Food and Drug Administration from 1998-2005. Twenty percent of the drugs accounted for 87% of the reports. Biotechnology products were linked with more than 9,000 events. The...

  • CAN THE FDA BE CURED? Gorman, Christine; Bacon Jr., Perry; Park, Alice; Thompson, Mark // Time International (South Pacific Edition);2/28/2005, Issue 8, p11 

    The article focuses on the U.S. Food and Drug Administration (FDA) and discusses the criticisms it is facing for not emphasizing the possibility of suicide risks and dangers of cardiac damage of antidepressants like Prozac and Vioxx and other painkillers. It emphasizes the role the FDA has...

  • The Importance of Reporting Negative Findings in Data Mining. Hauben, Manfred; Hochberg, Alan // Pharmaceutical Medicine - New Zealand;2008, Vol. 22 Issue 4, p215 

    The US Food and Drug Administration (FDA) recently published a warning regarding pancreatitis in association with the use of exenatide, an incretin mimetic used for the treatment of patients with diabetes mellitus. We note that this safety issue is not associated with a signal of...

  • FDA Leaves Darvon, Darvocet on Market; Adds Overdose Warnings. Young, Donna // BioWorld Today;7/8/2009, Vol. 20 Issue 129, p1 

    The article reports on the requirement imposed by the U.S. Food and Drug Administration for makers of propyxyphene-containing products like the opioid painkillers Darvon and Darvocet to include in its black-box warnings an alert about an increased risk of fatal overdoses when using the drugs....

  • FDA releases first quarterly drug safety report.  // Endocrine Today;11/10/2008, Vol. 6 Issue 20, p10 

    The article focuses on the release by the U.S. Food and Drug Administration (FDA) of its report of drugs under evaluation for potential safety issues. Included are duloxetine for urinary retention, icodextrin for hypoglycemia and insulin U-500 for dosing confusion. Physicians and patients were...

  • Effect of internal reporting criteria on suspected adverse drug reactions submitted to MedWatch. Smith, Kelly M.; Lawson, Amber P.; Tuteja, Sony // American Journal of Health-System Pharmacy;5/15/2006, Vol. 63 Issue 10, p950 

    The article focuses on the U.S. Food and Drug Administration's (FDA) reliance on voluntarily submitted adverse drug reaction (ADR) reports to assist in identifying postmarketing drug safety issues. MedWatch, the safety information and adverse-event reporting program of the FDA, receives 200,000...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics